Publications

Back to Publications

Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial

JAMA Cardiol. 2022; online ahead of print DOI: 10.1001/jamacardio.2022.3750

Dapagliflozin led to early and sustained reductions in clinical events. Time to first nominal statistical significance was 13 days for the primary endpoint and 16 days for worsening HF events. Significant benefits for the primary endpoint and worsening HF events were sustained at 30 days, 90 days, 6 months, 1 year and 2 years.


LinkedIn